Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death
- PMID: 19014912
- DOI: 10.1016/j.bcp.2008.10.019
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death
Abstract
The heat shock protein 90 (Hsp90) plays a crucial role in the stability of several proteins that are essential for malignant transformation. Hsp90 is therefore an interesting therapeutic target for cancer therapy. In this paper, we investigated whether an oxidative stress generated during ascorbate-driven menadione redox cycling (ascorbate/menadione), affects Hsp90 leading to the degradation of some critical proteins and cell death. Unlike 17-AAG, which inhibits Hsp90 but enhances Hsp70 levels, ascorbate/menadione-treated cells present an additional Hsp90 protein band of about 70kDa as shown by Western blot analysis, suggesting Hsp90 cleavage. This Hsp90 cleavage seems to be a selective phenomenon since it was observed in a large panel of cancer cell lines but not in non-transformed cells. Antibodies raised against either the N-terminus or the C-terminus domains of Hsp90 suggest that the site of cleavage should be located at its N-terminal part. Furthermore, antibodies raised against either the alpha- or the beta-Hsp90 isoform show that Hsp90beta is cleaved while the alpha isoform is down-regulated. We have further shown that different Hsp90 client proteins like Bcr-Abl (a chimerical protein expressed in K562 leukemia cells), RIP and Akt, were degraded when K562 cells were exposed to an oxidative stress. Both Hsp90 cleavage and Bcr-Abl degradation were observed by incubating K562 cells with another H(2)O(2)-generating system (glucose/glucose oxidase) and by incubating KU812 cells (another leukemia cell line) with ascorbate/menadione. Due to the major role of Hsp90 in stabilizing oncogenic and mutated proteins, these results may have potential clinical applications.
Similar articles
-
Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice.Biochem Pharmacol. 2006 Sep 14;72(6):671-80. doi: 10.1016/j.bcp.2006.05.025. Epub 2006 Jul 7. Biochem Pharmacol. 2006. PMID: 16828058
-
[The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].Zhonghua Yi Xue Za Zhi. 2006 Aug 29;86(32):2246-51. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17064567 Chinese.
-
Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.Acta Pharmacol Sin. 2006 Jun;27(6):694-9. doi: 10.1111/j.1745-7254.2006.00326.x. Acta Pharmacol Sin. 2006. PMID: 16723087
-
Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.Anticancer Res. 2009 Jun;29(6):2031-42. Anticancer Res. 2009. PMID: 19528462 Review.
-
Heat shock protein 90 as a drug target: some like it hot.Clin Cancer Res. 2009 Jan 1;15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132. Clin Cancer Res. 2009. PMID: 19118027 Review.
Cited by
-
Molecular targets of luteolin in cancer.Eur J Cancer Prev. 2016 Jan;25(1):65-76. doi: 10.1097/CEJ.0000000000000128. Eur J Cancer Prev. 2016. PMID: 25714651 Free PMC article. Review.
-
The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.Int J Oncol. 2019 Dec;55(6):1287-1295. doi: 10.3892/ijo.2019.4888. Epub 2019 Sep 30. Int J Oncol. 2019. PMID: 31638190 Free PMC article.
-
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.Redox Biol. 2017 Oct;13:470-476. doi: 10.1016/j.redox.2017.07.010. Epub 2017 Jul 12. Redox Biol. 2017. PMID: 28715732 Free PMC article.
-
Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy.Int J Mol Sci. 2024 Jul 2;25(13):7284. doi: 10.3390/ijms25137284. Int J Mol Sci. 2024. PMID: 39000393 Free PMC article. Review.
-
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.Invest New Drugs. 2011 Oct;29(5):891-900. doi: 10.1007/s10637-010-9441-3. Epub 2010 May 8. Invest New Drugs. 2011. PMID: 20454833
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous